Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT06076824

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Hospital General Universitario de Alicante (from the registry)
Registry
  • NCT NCT06076824
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06076824. Randomized; single masking; primary purpose prevention. Start 2023-08-12 (actual); primary completion 2024-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).
Acronym
GLUCO-TAVR
Condition
Heart Block
Condition
Aortic Stenosis
Condition
Bundle-Branch Block
Intervention (Drug)
Methylprednisolone
Intervention (Other)
Placebo
Lead sponsor
Hospital General Universitario de Alicante (class: other)

Record details

Record id
cardio:ct-nct06076824
Content hash
c0505de731589130409b65445d829bc73b4fe354bf2179cd35302d09f23ac817